57.20 0.00 (0.00%)
After hours: 5:15PM EDT
|Bid||57.17 x 900|
|Ask||57.21 x 900|
|Day's Range||55.51 - 57.53|
|52 Week Range||50.77 - 92.18|
|Beta (3Y Monthly)||1.33|
|PE Ratio (TTM)||51.62|
|Earnings Date||Jul 31, 2019 - Aug 5, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||65.00|
Mid-caps stocks, like Genomic Health, Inc. (NASDAQ:GHDX) with a market capitalization of US$2.0b, aren’t the focus of...
REDWOOD CITY, Calif., June 20, 2019 /PRNewswire/ -- Genomic Health announced today that the German Federal Joint Committee (G-BA) issued a positive reimbursement decision for the Oncotype DX Breast Recurrence Score® test during its plenary meeting session on June 20. According to the decision, Oncotype DX® will be the only multigene test reimbursed by statutory sick funds with wide national coverage, for use in all patients with primary node-negative, hormone receptor-positive, HER2-negative early-stage breast cancer when a decision for or against chemotherapy cannot be made based on clinical and pathological parameters alone. This decision follows the conclusion of the German Institute for Quality and Efficiency in Health Care (IQWiG) that only the Oncotype DX test has sufficient evidence to guide breast cancer adjuvant chemotherapy decisions based on results from the landmark TAILORx study1. Results from a recently published2 subset analysis of TAILORx confirm the original findings from the trial, showing that only the Breast Recurrence Score® test can assess the expected benefit of chemotherapy and that clinical and pathological features generally only provide prognostic information.
Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing […]
Genomic Health (GHDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Today we will run through one way of estimating the intrinsic value of Genomic Health, Inc. (NASDAQ:GHDX) by taking...
Wall Street soured on the high-growth industry after first-quarter earnings were reported, but it may have been an overreaction for two stocks.
REDWOOD CITY, Calif., June 3, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that results from a new analysis of the Trial Assigning IndividuaLized Options for Treatment (Rx), or TAILORx, confirm the original, definitive conclusions reported last year with additional detail on clinical risk, focusing on patients with early-stage breast cancer who are age 50 years or younger. Clinical risk provides prognostic information that is complementary to the Oncotype DX Breast Recurrence Score® test and may help identify younger women who benefit from more effective therapy.
REDWOOD CITY, Calif., June 3, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that its Oncotype DX Breast Recurrence Score® test and the TAILORx results have been recommended to guide chemotherapy treatment use in patients with node-negative early-stage breast cancer by the American Society of Clinical Oncology (ASCO) in its 2019 Guidelines for Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy. Using the strong and highest level of evidence from TAILORx, the updated ASCO guidelines increase the proportion of women who can be effectively treated without chemotherapy based on the Oncotype DX® results, highlighting the importance of testing all medically eligible patients as standard of care.
REDWOOD CITY, Calif. , May 29, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that management will present at the Jefferies 2019 Healthcare Conference in New York City on Wednesday, ...
These companies could make a big difference in how the disease is diagnosed and treated. And their stocks could make a big difference for long-term investors.
According to the Centers for Medicare and Medicaid Services, healthcare spending will rise 5.5% annually through 2026, when that spending will represent 20% of the country's GDP; a boon for healthcare stocks.To put this in perspective, the U.S. defense budget is about 18% of the entire U.S. budget and we outspend every other nation on this planet in defense spending by a significant margin.The U.S. healthcare system is being debated again and may well be a significant issue in the upcoming presidential election.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut the reality is, the U.S. population is getting older and that means more chronic diseases begin to take their toll. Also, older people tend to take up a larger portion of healthcare costs as their health begins to fail. * 7 High-Yield REITs to Buy (Even When the Market Tanks) That means there will be an unstoppable growth trend in place for healthcare companies. The A-rated healthcare stocks I feature here are well placed to take advantage of this trend. And they're small enough that their growth will outpace their larger competitors and may make them interesting takeover targets.Source: Flickr Masimo (MASI)Masimo Corp (NASDAQ:MASI) is the perfect example of how technology is transforming healthcare.Once, heading the doctors or the hospital was a regular occurrence for patients with chronic issues like heart disease or diabetes. But now, monitoring technologies, where patients can wear a device that essentially tracks their functions and the data can either be downloaded remotely or by the patient and sent to the doctor, are becoming increasingly common.And MASI is one of the leaders in the field. It is also one of the two top players in the pulse oximetry sector. These are devices that check the oxygen saturation level a person's blood. Hospitals use these a great deal and generally the contracts run on a five-year basis, so income is steady and once they're in place it's unlikely the hospitals will switch over to a new type of unit, so there are solid competitive moats.MASI is up almost 44% in the past 12 months, and much of that has come in 2019. This is the kind of company that can grow with the market regardless of what U.S. healthcare ends up looking like.Source: Shutterstock Ionis Pharmaceuticals (IONS)Ionis Pharmaceuticals (NASDAQ:IONS) was founded by leading biotech scientists to expand the use of antisense therapy. It's a new form of treatment that is at the cutting edge of science medicine.Basically, if you can find a genetic marker for a disease, you can synthesize a strand of RNA that can render that gene inactive, so it doesn't reproduce. The potential uses extend to cancers, heart disease, diabetes, asthma, arthritis … the list goes on. * 6 Chinese Stocks That Could Pop On a Trade Deal This technology has the potential to help both rare and common maladies, many of which don't have current effective treatments.IONS is already partnered with a number of larger pharmaceutical firms and is up 55% in the past year, with plenty of headroom left.Source: Shutterstock Osiris Therapeutics (OSIR)Osiris Therapeutics (NASDAQ:OSIR) has a market cap around $650 million, so it's in that perfect spot where it has the potential for big growth on its own, or it could be a target for takeover at a nice premium for a larger pharma looking for a unique product line.OSIR specializes in regenerative medicine products. What that means is, it uses stem cells to build medicines that help everything from wound healing to bone marrow graft acceptance. It's a unique space that has significant possibilities now and for the future.It currently has five products on the market that are focused on wound healing, ligament repairs and surgical wraps on tissues. All promote better healing outcomes with less infections than traditional methods.Last quarter it sold the rights to one of its top stem cell drug for $100 million, so it's work is being recognized. OSIR stock is up 141% for the year and 40% in 2019.Source: Shutterstock Ensign Group (ENSG)Ensign Group (NASDAQ:ENSG) specializes in post-acute care staffing for a wide variety of facilities that would need these services. Some of the most obvious would be assisted living facilities, home health care, rehab facilities and hospice. It manages 250 companies in more than 12 states, around the U.S.This is precisely the sort of sector that will be in huge demand in coming years. While all the technology and new drugs are great, there will still need to be qualified people helping support the patients as they recover and attempt to maintain active lifestyles. * 10 Retirement Stocks That Won't Wilt in a Bear Market It continues to expand its base in California, where the company is headquartered, having just bought another company in Southern California. But its operations beyond the state show that it has what it takes to expand its model where the most opportunity is.Up 59% in the past year, its size makes it a potential takeover target or a big grower on its own.Source: Shutterstock Genomic Health (GHDX)Genomic Health (NASDAQ:GHDX) specializes in genomic diagnostic testing, specifically for cancer. The testing allows for patients and doctors to create individualized treatment strategies for patients.This is important because it means patients get the treatment they need -- they're not over-treated or under-treated. And that is good for the whole healthcare system as well as the patients.Again, this kind of diagnostic tool will be something that insurers, hospitals and patients can get behind since it allows care to better suited to each patient with the goal of lowering costs and improving outcomes.The stock is up over 38% in the past year and it's still going strong.Source: Shutterstock National Research Corp (NRC)National Research (NASDAQ:NRC) is all about delivering all the best possible outcomes for patients with their healthcare providers. NRC sees the current and future healthcare sector as patient-driven, and that is not the traditional model.The patient wasn't much more than a bundle of symptoms that were inserted into the healthcare machines to get repaired and sent back out into the world before. Now, it's about creating an experience that not only serves the patient better, but is able to deliver better outcomes and fewer return visits. It's looking at numbers that view the system more holistically.And NRC provides those numbers from its research. * 7 Cloud Stocks to Buy on Overcast Days While it has been around since 1981, NRC is just coming into its own. And it would be a great takeover target for one of the big healthcare insurers or a large hospital chain.Up 26% in the past year, NRC also delivers a nearly a 2% dividend.Source: Shutterstock AngioDynamics (NASDAQ:ANGO) is a medical device company that specializes in equipment that's used for vascular access, surgery, vascular disease and oncology. It actually made a new acquisition earlier this year to increase its oncology suite of products.Specialty medical device makers are in particular demand globally, since the good ones tend to get most of the business. Medicine is a very conservative practice and tested and true is much more preferable to new and interesting.And generally that's the view from hospitals, insurers and patients. It takes years to put new equipment in place and generally the new equipment is from a trusted equipment maker and not the kid on the block. Having been around since 1988, ANGO fits that bill.Although its global potential looks huge as China looks to upgrade its entire healthcare system, it's been volatile over the last year and relatively flat (actually down .3%). Most of the volatility is trade war related and that can't last forever.Louis Navellier is a renowned growth investor. He is the editor of four investing newsletters: Growth Investor, Breakthrough Stocks, Accelerated Profits and Platinum Growth. His most popular service, Growth Investor, has a track record of beating the market 3:1 over the last 14 years. He uses a combination of quantitative and fundamental analysis to identify market-beating stocks. Mr. Navellier has made his proven formula accessible to investors via his free, online stock rating tool, PortfolioGrader.com. Louis Navellier may hold some of the aforementioned securities in one or more of his newsletters. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 7 A-Rated Healthcare Stocks for Industry Expansion appeared first on InvestorPlace.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! While some investors are already well versed in financial metrics (hat tip), this article is for thos...
On a per-share basis, the Redwood City, California-based company said it had profit of 34 cents. The results surpassed Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Delivered $108.8M in Revenue and Growth of 17.4 Percent Achieved Significant Revenue Growth for All Key Product Areas Reported $13.0M in Profit and EPS of $0.34 Per Share on a Diluted Basis REDWOOD CITY, ...
REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern ...
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of December 31st. In this article we look at what those investors think of Genomic Health, Inc. (NASDAQ:GHDX). Is Genomic Health, […]